Arrowhead’s RNAi Gaining Momentum In Heart And Lung Targets
Shares Up By 25% On Pipeline Progress
Arrowhead has spent years in the shadows of rivals Alnylam and Ionis, but could make its mark with new ways to target cardiovascular and lung disease using RNA interference.
